Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Clinical Trials Approvals

Lixisenatide data underpin Zealand Pharma ambitions

This article was originally published in Scrip

Executive Summary

Zealand Pharma, the Danish peptide drug discovery company, moved a step closer today in establishing itself as an emerging force in the control of diabetes. Its partner Sanofi-Aventis has announced positive top-line results from the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, Zealand's once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with French pharma's long-acting insulin Lantus (insulin glargine), in type 2 diabetes patients.

Table

View full table

Topics

Related Companies

Tags:
Metabolic Disorders Clinical Trials Approvals
Latest Headlines

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

See All
UsernamePublicRestriction

Register

SC010326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By